Sunesis Pharmaceuticals Announces Presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and ...
October 27 2015 - 3:28PM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced two
poster presentations at the 2015 AACR-NCI-EORTC International
Conference on Molecular Targets and Cancer Therapeutics being held
November 5-9 in Boston, Massachusetts.
The details for the poster presentations are as follows:
Date and Time: Sunday,
November 8, 2015 from 12:30 p.m. to 3:30 p.m. Eastern Time |
Poster Title: PDK1
inhibitors SNS-229 and SNS-510 cause pathway modulation, apoptosis
and tumor regression in hematologic cancer models in addition to
solid tumors |
Abstract/Poster Number:
C198 |
Session Title: Therapeutic
Agents: Small Molecule Kinase Inhibitors |
Session ID: Poster Session
C |
Location: Exhibit Hall
C-D |
|
The full abstract can be viewed here. |
|
Date and Time: Sunday,
November 8, 2015 from 12:30 p.m. to 3:30 p.m. Eastern Time |
Poster Title: SNS-062 is a
potent noncovalent BTK inhibitor with comparable activity against
wild type BTK and BTK with an acquired resistance mutation |
Abstract/Poster Number:
C186 |
Session Title: Therapeutic
Agents: Small Molecule Kinase Inhibitors |
Session ID: Poster Session
C |
Location: Exhibit Hall
C-D |
|
The full abstract can be viewed here. |
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the
development and commercialization of new oncology therapeutics for
the potential treatment of solid and hematologic cancers. Sunesis
has built a highly experienced cancer drug development organization
committed to advancing its lead product candidate, vosaroxin, in
multiple indications to improve the lives of people with
cancer.
For additional information on Sunesis, please visit
http://www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis
Pharmaceuticals, Inc.
This press release contains forward-looking statements,
including statements related to Sunesis' estimated timelines for
regulatory interactions and regulatory progress, including the
anticipated submission of the MAA for vosaroxin with the EMA and
plans to gain marketing approval of vosaroxin in the U.S., Sunesis'
overall strategy, the design, conduct and results of clinical
trials, including the expected progress in its kinase inhibitor
pipeline, estimated new cases of AML, its prevalence across major
global markets, prognosis for patients with AML, the need for and
the role of vosaroxin as a potential new treatment option, and
Sunesis' clinical development of vosaroxin, including the analysis
of the results from the VALOR clinical trial. Words such as
"anticipates," "estimates," "expect," "intends," "plan,"
"potential," "will" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Sunesis' current expectations.
Forward-looking statements involve risks and uncertainties.
Sunesis' actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation, the risk that Sunesis may not be able
to submit timely the MAA to the EMA, the risk that Sunesis'
clinical studies for vosaroxin may not lead to regulatory approval
in the U.S. or Europe, that Sunesis' development activities for
vosaroxin could be otherwise halted or significantly delayed for
various reasons, the risk that Sunesis' clinical studies for
vosaroxin or other product candidates may not demonstrate safety or
efficacy or lead to regulatory approval, the risk that data to date
and trends may not be predictive of future data or results, risks
related to the conduct of Sunesis' clinical trials, risks related
to Sunesis' need for substantial additional funding to complete the
development and commercialization of vosaroxin, and risks related
to Sunesis' ability to raise the capital that it believes to be
accessible and is required to fully finance the development and
commercialization of vosaroxin. These and other risk factors are
discussed under "Risk Factors" and elsewhere in Sunesis' Quarterly
Report on Form 10-Q for the quarter ended June 30, 2015. Sunesis
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in Sunesis' expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statements are based.
CONTACT: Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Oct 2023 to Oct 2024